You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 1383 Preclinical characterization of D3L-002, a novel cancer immunotherapy bispecific antibody that elicits potent anti-tumor efficacy via co-blocking TIGIT and PVRIG

Share

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1383 Preclinical characterization of D3L-002, a novel cancer immunotherapy bispecific antibody that elicits potent anti-tumor efficacy via co-blocking TIGIT and PVRIG

Share this article

Click the icon of the social media platform on which you would like to share this article.

Twitter logo Facebook logo LinkedIn logo

Email this article to a friend

We will not keep your email address; we ask for it so your friend knows the email isn't spam.
Enter multiple addresses on separate lines or separate them with commas.
1383 Preclinical characterization of D3L-002, a novel cancer immunotherapy bispecific antibody that elicits potent anti-tumor efficacy via co-blocking TIGIT and PVRIG
(Your Name) has forwarded a page to you from Journal for ImmunoTherapy of Cancer
(Your Name) thought you would like to see this page from the Journal for ImmunoTherapy of Cancer web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.